ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.
Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.
Location: United States, New Jersey, Princeton
Member count: 1-10
Total raised: $20M
Investors 2
| Date | Name | Website |
| 19.04.2022 | Insight Pa... | insightpar... |
| 07.04.2022 | Innospark ... | innosparkv... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 04.03.2022 | Seed | $20M | - | finsmes.co... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 26.05.2022 | Portfolio ... | SHANGHAI, May 26, 2022 /PRNews... | - | - | en.prnasia... |
| 07.03.2022 | ArrePath A... | ArrePath, an anti-infective dr... | - | - | aithority.... |
| 04.03.2022 | ArrePath R... | Dr. Lloyd Payne, ArrePath Pres... | USA | - | finsmes.co... |
| 03.03.2022 | Drug disco... | Photo: filadendron/Getty Image... | - | Emily Olse... | mobihealth... |
| - | Princeton ... | Antibiotic resistance is a gro... | - | - | medcitynew... |